FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

LEE WILLIS C		 2. Issuer Name and Ticker or Trading Symbol

Emmaus Life Sciences, Inc. [ EMMA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Vice Chairman & COO
(Last)          (First)          (Middle)

21250 HAWTHORNE BLVD., SUITE 800		 3. Date of Earliest Transaction (MM/DD/YYYY)

10/31/2019
(Street)

TORRANCE, CA 90503
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock, $0.001 par value  10/31/2019    P    1000  A $2.90  207274  D   
Common stock, $0.001 par value  11/1/2019    P    800  A $2.98 (1) 208074  D   
Common stock, $0.001 par value                 75761  I  By Pensco Trust Company LLC FBO Willis C. Lee 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.89 to $2.99, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
LEE WILLIS C
21250 HAWTHORNE BLVD.
SUITE 800
TORRANCE, CA 90503 		X
Vice Chairman & COO

Signatures
Willis C. Lee 11/1/2019
**Signature of Reporting Person Date


MYnd Analytics, Inc. (NASDAQ:MYND)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more MYnd Analytics, Inc. Charts.
MYnd Analytics, Inc. (NASDAQ:MYND)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more MYnd Analytics, Inc. Charts.

Emmaus Life Sciences, Inc. News

Real-Time news about Mynd Analytics, Inc. (NASDAQ): 0 recent articles

More Emmaus Life Sciences, Inc. News Articles

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.